证券代码：605116 证券简称：奥锐特 公告编号：2025-058 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 不超过 1 亿元 | | --- | --- | | 投资种类 | 用于投资安全性高、流动性好的保本型理财产品或存 | | | 款类产品，产品期限不超过 12 个月 | | 资金来源 | 募集资金 | 已履行及拟履行的审议程序 公司于 2025 年 8 月 27 日召开第三届董事会第十五次会议及第三届监事会第 十二次会议分别审议通过了《关于使用部分闲置募集资金进行现金管理的议案》， 保荐人发表了同意意见，本次事项无需提交股东大会审议。 特别风险提示 尽管公司本次拟购买的现金管理产品属于低风险理财品种，但金融市场受宏 观经济、财政及货币政策的影响较大，不排除相关投资可能受到市场波动的影响， 从而影响预期收益。 一、募集资金基本情况 经中国证券监督管理委员会《关 ...

奥锐特药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布 公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年 度的经营成果、财务状况，公司计划于 2025 年 09 月 15 日下午 14:00-14:45 举 行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 证券代码：605116 证券简称：奥锐特 公告编号：2025-061 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 8 日（星期一）至 9 月 12 日（星期五）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aurisco. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 四、投资者参加方式 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2025 年半年度 ...

Core Insights - The company reported total assets of 3.903 billion yuan at the end of the reporting period, representing a 0.65% increase compared to the end of the previous year [1] - The net assets attributable to shareholders of the listed company reached 2.429 billion yuan, showing a year-on-year increase of 4.19% [1] - The operating revenue for the period was 822 million yuan, reflecting a year-on-year growth of 12.50% [1] - The total profit amounted to 268 million yuan, which is a 23.66% increase compared to the previous year [1] - The net profit attributable to shareholders of the listed company was 235 million yuan, marking a year-on-year increase of 24.55% [1] - The net cash flow from operating activities was 215 million yuan, up 28.71% year-on-year [1] - The top 10 shareholders include Zhejiang Tongben Investment Co., Ltd. and Chu Yizhou, holding 37.81% and 27.65% of shares respectively [1]

Group 1 - The company, Aorite (605116.SH), stated that it is currently not involved in any antibiotic-related business [1]

通过天眼查大数据分析，奥锐特药业股份有限公司共对外投资了10家企业，参与招投标项目58次，知识 产权方面有商标信息40条，专利信息76条，此外企业还拥有行政许可63个。 来源：金融界 奥锐特最新一期业绩显示，截至2025一季报，公司营业总收入4.02亿元、同比增长19.78%，归属净利润 1.19亿元，同比增长45.30%，扣非净利润1.13亿元，同比增长37.51%，流动比率4.618、速动比率 3.214、资产负债率37.37%。 天眼查商业履历信息显示，奥锐特药业股份有限公司，成立于1998年，位于台州市，是一家以从事医药 制造业为主的企业。企业注册资本40619.5万人民币，实缴资本40619.5万人民币。公司法定代表人为彭 志恩。 金融界消息 截至2025年8月19日收盘，奥锐特（605116）报收于25.03元，上涨4.55%，换手率4.17%， 成交量16.57万手，成交金额4.25亿元。 资金流向方面，今日主力资金净流入7522.44万元，占比成交额17.7%。其中，超大单净流入6474.49万 元、占成交额15.23%，大单净流入1047.95万元、占成交额2.47%，中单净流出流出2812 ...

Core Viewpoint - The weight loss drug sector is experiencing significant fluctuations, with several companies seeing substantial stock price increases [1] Company Summary - Boji Pharmaceutical (300404) and Ganli Pharmaceutical (603087) have reached their daily price limit increase [1] - Aorite (605116), Deyuan Pharmaceutical, and Meinuohua (603538) are also witnessing stock price increases, indicating a broader trend in the sector [1]

Core Insights - The report highlights the significant role of company secretaries (董秘) as a bridge between investors and listed companies, emphasizing their importance in capital operations within the A-share market [1] Salary Overview - The total salary for A-share company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - In the raw material pharmaceutical sector, the average annual salary for company secretaries is 608,400 yuan [1] Demographics - The age distribution shows that 60% of company secretaries are between 30-50 years old, while 38% are over 50, and only 2% are 30 or younger [1] - Educational background indicates that over 50% of company secretaries hold a bachelor's degree, with 9% having an associate degree, 39% holding a master's degree [1] Salary Distribution in Raw Material Pharmaceutical Sector - Among company secretaries in the raw material pharmaceutical sector, 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn over 1 million yuan [1] Top Earners - The top five highest-paid company secretaries are from Guobang Pharmaceutical, Saifen Technology, Keyuan Pharmaceutical, Aorite, and Zhejiang Pharmaceutical, with salaries ranging from 1.0832 million to 1.9309 million yuan [2] - The lowest-paid company secretaries earn below 200,000 yuan, with their salaries ranging from 174,200 to 190,700 yuan [2]

Core Viewpoint - The announcement details a share reduction plan by a senior executive of Aorite Pharmaceutical Co., Ltd. due to personal financial needs, involving a maximum reduction of 62,500 shares, which is 0.02% of the total share capital [2][3]. Group 1: Executive Shareholding Information - As of the announcement date, the total number of shares for Aorite Pharmaceutical is 406,195,234, with the executive Zhao Zhenping holding 250,000 shares, representing 0.06% of the total share capital [2]. Group 2: Reduction Plan Details - The executive plans to reduce shares through centralized bidding within three months after the announcement, starting 15 trading days later, with a maximum of 62,500 shares to be sold [3]. - The reduction will not exceed 25% of the executive's total shareholding, and any changes in share capital due to dividends or other corporate actions will adjust the reduction quantity accordingly [3]. Group 3: Other Relevant Information - The executive has no concerted actions with other shareholders and has made prior commitments regarding shareholding and reduction methods [4][6]. - The company will monitor the reduction plan and comply with relevant regulations, ensuring timely disclosure of any developments [9][17].

据统计，8月4日，盘后包括达意隆、山外山、开普检测、吉宏股份、红旗连锁、通达股份、神火股份、 康泰医学、步科股份、飞鹿股份、能辉科技、晶雪节能、胜宏科技、赛腾股份、雪迪龙、中芯国际、工 大高科、成都先导、飞乐音响、华电辽能、三维股份、奥锐特在内的22家A股上市公司披露减持情况。 当日暂无A股上市公司披露增持情况。 | 1 | 达意障 | 董事兼高级管理人员吴小满计划减持不超过4.22万股股份 | | --- | --- | --- | | 2 | 山外山 | 大健康和力远健鲲合计减持2.26%公司股份 | | 3 | 开普检测 | 副总经理贺春、张冉拟减持不超过0.54%公司股份 | | 4 | 吉宏股份 | 毒事长干亚朋计划减持不超过304万股 | | 5 | 红旗连锁 | 永辉超市拟减持不超过1%股份 | | 6 | 通达股份 | 控股股东拟减持不超过3%公司股份 | | 1 | 神火股份 | 普天工贸拟减持0.90%公司股份 | | 8 | 康泰医学 | 持股5%以上股东及部分董事、高管拟减持不超过3.59%股份 | | 9 | 步科股份 | 控股股东上海步进计划减持不超过3%公司股份 | | 10 | ...

（编辑 任世碧） 证券日报网讯 8月4日晚间，奥锐特发布公告称，截至2025年7月31日，公司通过上海证券交易所交易系 统以集中竞价交易方式已累计回购公司股份141.42万股，占公司目前总股本的比例为0.35%。 ...